Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research

Supportive Care in Cancer

Volumn 20, Issue 4, 2012, Pages 831-839

  Janelsins, Michelle C ^a   Mustian, Karen M ^a   Palesh, Oxana G ^b   Mohile, Supriya G ^a   Peppone, Luke J ^a   Sprod, Lisa K ^a   Heckler, Charles E ^a   Roscoe, Joseph A ^a   Katz, Alan W ^a   Williams, Jacqueline P ^a   Morrow, Gary R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Cancer; Chemotherapy; Cognitive impairment; Cytokines; Immune response

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PAROXETINE; PLACEBO;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOKINE CCL2; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; TIME FACTORS;

EID: 84863477803     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1158-0     Document Type: Article

References (27)

1. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. doi:10.1200/JCO.2009.27.0827
2. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR (2010) An update on cancer- and chemotherapy-related cognitive difficulties: current status. Sem Onc (in press)
3. Ahles TA, Saykin AJ (2002) Breast cancer chemotherapyrelated cognitive dysfunction. Clin Breast Cancer 3(Suppl 3): S84-S90
4. Ahles TA, Saykin A (2001) Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19(8):812-820
5. Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116(1):113-123. doi:10.1007/s10549-008-0114-2
6. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292-2299. doi:10.1002/cncr.20272
7. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348-3356. doi:10.1002/cncr.25098
8. Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14(11):1111-1118. doi:10.1007/s00520-006-0037-6
9. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26(7):955-969
10. Janelsins MC, Roscoe JA, Palesh OG, Mustian KM, Peppone LJ, Heckler CE, Morrow GR (2010) Cognitive difficulties, fatigue, and sleep in cancer patients at pre-chemotherapy, postchemotherapy, and at three months follow-up. Annals Behav Med 39(S1); abstract
11. Magaki S, Mueller C, Dickson C, Kirsch W (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42(3):233-240. doi:10.1016/j.exger.2006.09.015
12. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63 (4):538-543. doi:10.1001/archneur.63.4.538
13. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E (2006) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging 27 (12):1763-1768. doi:10.1016/j.neurobiolaging.2005.10.007
14. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68(22):1902-1908. doi:10.1212/01.wnl.0000263217.36439.da
15. Van Den Heuvel C, Thornton E, Vink R (2007) Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 161:303-316
16. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7 (3):192-201. doi:10.1038/nrc2073
17. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97(11):2919-2925. doi:10.1002/cncr.11382
18. Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V (2008) Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori 94(6):803-808
19. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102
20. Mills PJ, Ancoli-Israel S, Parker B, Natarajan L, Hong S, Jain S, Sadler GR, von Kanel R (2008) Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav Immun 22(1):98-104. doi:10.1016/j.bbi.2007.07.001
21. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R, Smith B (2005) Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89(3):243-249. doi:10.1007/s10549-004-2175-1
22. Yoshitake H (1978) Three characteristic patterns of subjective fatigue symptoms. Ergonomics 21(3):231-233
23. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St Clair W, Ratanachaiyavong S, St Clair DK, Butterfield DA (2006) Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 23(1):127-139. doi:10.1016/j.nbd.2006.02.013
24. Liedke PE, Reolon GK, Kilpp B, Brunetto AL, Roesler R, Schwartsmann G (2009) Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 94(2):239-243. doi:10.1016/j.pbb.2009. 09.001
25. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60(8):729-735
26. Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, Villaggio B (2000) Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 27(11):2551-2557
27. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153(9):4159-4168